United States Choroidal Neovascularization Drug Market Report 2017

December 2017 | 108 pages | ID: U0D23F7ED2EEN
QYResearch

Abstracts

In this report, the United States Choroidal Neovascularization Drug market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:

• The West
• Southwest
• The Middle Atlantic
• New England
• The South
• The Midwest
• with sales (volume), revenue (value), market share and growth rate of Choroidal Neovascularization Drug in these regions, from 2012 to 2022 (forecast).

United States Choroidal Neovascularization Drug market competition by top manufacturers/players, with Choroidal Neovascularization Drug sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including

• Cellphire, Inc.
• Chrysalis BioTherapeutics, Inc.
• Cleveland BioLabs, Inc.
• Cumberland Pharmaceuticals, Inc.
• Diffusion Pharmaceuticals Inc.
• Eli Lilly and Company
• GNI Group Ltd.
• Humanetics Corporation
• INSYS Therapeutics, Inc.
• Meabco A/S
• Neumedicines Inc.
• Onconova Therapeutics, Inc.
• PharmaIN Corporation
• Pluristem Therapeutics Inc.
• ProCertus BioPharm Inc.
• RDD Pharma Ltd.
• RedHill Biopharma Ltd.
• RxBio, Inc.
• Soligenix, Inc.

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

• AVMOC-001
• BB-3
• BBT-007
• DG-3
• Entolimod
• EWA-001
• Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including

• Clinic
• Hospital
• Others

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

United States Choroidal Neovascularization Drug Market Report 2017

1 CHOROIDAL NEOVASCULARIZATION DRUG OVERVIEW

1.1 Product Overview and Scope of Choroidal Neovascularization Drug
1.2 Classification of Choroidal Neovascularization Drug by Product Category
  1.2.1 United States Choroidal Neovascularization Drug Market Size (Sales Volume) Comparison by Type (2012-2022)
  1.2.2 United States Choroidal Neovascularization Drug Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
  1.2.3 AVMOC-001
  1.2.4 BB-3
  1.2.5 BBT-007
  1.2.6 DG-3
  1.2.7 Entolimod
  1.2.8 EWA-001
  1.2.9 Others
1.3 United States Choroidal Neovascularization Drug Market by Application/End Users
  1.3.1 United States Choroidal Neovascularization Drug Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
  1.3.2 Clinic
  1.3.3 Hospital
  1.3.4 Others
1.4 United States Choroidal Neovascularization Drug Market by Region
  1.4.1 United States Choroidal Neovascularization Drug Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 The West Choroidal Neovascularization Drug Status and Prospect (2012-2022)
  1.4.3 Southwest Choroidal Neovascularization Drug Status and Prospect (2012-2022)
  1.4.4 The Middle Atlantic Choroidal Neovascularization Drug Status and Prospect (2012-2022)
  1.4.5 New England Choroidal Neovascularization Drug Status and Prospect (2012-2022)
  1.4.6 The South Choroidal Neovascularization Drug Status and Prospect (2012-2022)
  1.4.7 The Midwest Choroidal Neovascularization Drug Status and Prospect (2012-2022)
1.5 United States Market Size (Value and Volume) of Choroidal Neovascularization Drug (2012-2022)
  1.5.1 United States Choroidal Neovascularization Drug Sales and Growth Rate (2012-2022)
  1.5.2 United States Choroidal Neovascularization Drug Revenue and Growth Rate (2012-2022)

2 UNITED STATES CHOROIDAL NEOVASCULARIZATION DRUG MARKET COMPETITION BY PLAYERS/SUPPLIERS

2.1 United States Choroidal Neovascularization Drug Sales and Market Share of Key Players/Suppliers (2012-2017)
2.2 United States Choroidal Neovascularization Drug Revenue and Share by Players/Suppliers (2012-2017)
2.3 United States Choroidal Neovascularization Drug Average Price by Players/Suppliers (2012-2017)
2.4 United States Choroidal Neovascularization Drug Market Competitive Situation and Trends
  2.4.1 United States Choroidal Neovascularization Drug Market Concentration Rate
  2.4.2 United States Choroidal Neovascularization Drug Market Share of Top 3 and Top 5 Players/Suppliers
  2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Choroidal Neovascularization Drug Manufacturing Base Distribution, Sales Area, Product Type

3 UNITED STATES CHOROIDAL NEOVASCULARIZATION DRUG SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2012-2017)

3.1 United States Choroidal Neovascularization Drug Sales and Market Share by Region (2012-2017)
3.2 United States Choroidal Neovascularization Drug Revenue and Market Share by Region (2012-2017)
3.3 United States Choroidal Neovascularization Drug Price by Region (2012-2017)

4 UNITED STATES CHOROIDAL NEOVASCULARIZATION DRUG SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2012-2017)

4.1 United States Choroidal Neovascularization Drug Sales and Market Share by Type (Product Category) (2012-2017)
4.2 United States Choroidal Neovascularization Drug Revenue and Market Share by Type (2012-2017)
4.3 United States Choroidal Neovascularization Drug Price by Type (2012-2017)
4.4 United States Choroidal Neovascularization Drug Sales Growth Rate by Type (2012-2017)

5 UNITED STATES CHOROIDAL NEOVASCULARIZATION DRUG SALES (VOLUME) BY APPLICATION (2012-2017)

5.1 United States Choroidal Neovascularization Drug Sales and Market Share by Application (2012-2017)
5.2 United States Choroidal Neovascularization Drug Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities

6 UNITED STATES CHOROIDAL NEOVASCULARIZATION DRUG PLAYERS/SUPPLIERS PROFILES AND SALES DATA

6.1 Cellphire, Inc.
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Choroidal Neovascularization Drug Product Category, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Cellphire, Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 Chrysalis BioTherapeutics, Inc.
  6.2.2 Choroidal Neovascularization Drug Product Category, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 Cleveland BioLabs, Inc.
  6.3.2 Choroidal Neovascularization Drug Product Category, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 Cumberland Pharmaceuticals, Inc.
  6.4.2 Choroidal Neovascularization Drug Product Category, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 Diffusion Pharmaceuticals Inc.
  6.5.2 Choroidal Neovascularization Drug Product Category, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview
6.6 Eli Lilly and Company
  6.6.2 Choroidal Neovascularization Drug Product Category, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 Eli Lilly and Company Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Main Business/Business Overview
6.7 GNI Group Ltd.
  6.7.2 Choroidal Neovascularization Drug Product Category, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 GNI Group Ltd. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2012-2017)
  6.7.4 Main Business/Business Overview
6.8 Humanetics Corporation
  6.8.2 Choroidal Neovascularization Drug Product Category, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 Humanetics Corporation Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2012-2017)
  6.8.4 Main Business/Business Overview
6.9 INSYS Therapeutics, Inc.
  6.9.2 Choroidal Neovascularization Drug Product Category, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2012-2017)
  6.9.4 Main Business/Business Overview
6.10 Meabco A/S
  6.10.2 Choroidal Neovascularization Drug Product Category, Application and Specification
    6.10.2.1 Product A
    6.10.2.2 Product B
  6.10.3 Meabco A/S Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2012-2017)
  6.10.4 Main Business/Business Overview
6.11 Neumedicines Inc.
6.12 Onconova Therapeutics, Inc.
6.13 PharmaIN Corporation
6.14 Pluristem Therapeutics Inc.
6.15 ProCertus BioPharm Inc.
6.16 RDD Pharma Ltd.
6.17 RedHill Biopharma Ltd.
6.18 RxBio, Inc.
6.19 Soligenix, Inc.

7 CHOROIDAL NEOVASCULARIZATION DRUG MANUFACTURING COST ANALYSIS

7.1 Choroidal Neovascularization Drug Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Choroidal Neovascularization Drug

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Choroidal Neovascularization Drug Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Choroidal Neovascularization Drug Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 UNITED STATES CHOROIDAL NEOVASCULARIZATION DRUG MARKET SIZE (VALUE AND VOLUME) FORECAST (2017-2022)

11.1 United States Choroidal Neovascularization Drug Sales Volume, Revenue Forecast (2017-2022)
11.2 United States Choroidal Neovascularization Drug Sales Volume Forecast by Type (2017-2022)
11.3 United States Choroidal Neovascularization Drug Sales Volume Forecast by Application (2017-2022)
11.4 United States Choroidal Neovascularization Drug Sales Volume Forecast by Region (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer


The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of Choroidal Neovascularization Drug
Figure United States Choroidal Neovascularization Drug Market Size (K Pcs) by Type (2012-2022)
Figure United States Choroidal Neovascularization Drug Sales Volume Market Share by Type (Product Category) in 2016
Figure AVMOC-001 Product Picture
Figure BB-3 Product Picture
Figure BBT-007 Product Picture
Figure DG-3 Product Picture
Figure Entolimod Product Picture
Figure EWA-001 Product Picture
Figure Others Product Picture
Figure United States Choroidal Neovascularization Drug Market Size (K Pcs) by Application (2012-2022)
Figure United States Sales Market Share of Choroidal Neovascularization Drug by Application in 2016
Figure Clinic Examples
Table Key Downstream Customer in Clinic
Figure Hospital Examples
Table Key Downstream Customer in Hospital
Figure Others Examples
Table Key Downstream Customer in Others
Figure United States Choroidal Neovascularization Drug Market Size (Million USD) by Region (2012-2022)
Figure The West Choroidal Neovascularization Drug Revenue (Million USD) and Growth Rate (2012-2022)
Figure Southwest Choroidal Neovascularization Drug Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Middle Atlantic Choroidal Neovascularization Drug Revenue (Million USD) and Growth Rate (2012-2022)
Figure New England Choroidal Neovascularization Drug Revenue (Million USD) and Growth Rate (2012-2022)
Figure The South of US Choroidal Neovascularization Drug Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Midwest Choroidal Neovascularization Drug Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Choroidal Neovascularization Drug Sales (K Pcs) and Growth Rate (2012-2022)
Figure United States Choroidal Neovascularization Drug Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Choroidal Neovascularization Drug Market Major Players Product Sales Volume (K Pcs) (2012-2017)
Table United States Choroidal Neovascularization Drug Sales (K Pcs) of Key Players/Suppliers (2012-2017)
Table United States Choroidal Neovascularization Drug Sales Share by Players/Suppliers (2012-2017)
Figure 2016 United States Choroidal Neovascularization Drug Sales Share by Players/Suppliers
Figure 2017 United States Choroidal Neovascularization Drug Sales Share by Players/Suppliers
Figure United States Choroidal Neovascularization Drug Market Major Players Product Revenue (Million USD) (2012-2017)
Table United States Choroidal Neovascularization Drug Revenue (Million USD) by Players/Suppliers (2012-2017)
Table United States Choroidal Neovascularization Drug Revenue Share by Players/Suppliers (2012-2017)
Figure 2016 United States Choroidal Neovascularization Drug Revenue Share by Players/Suppliers
Figure 2017 United States Choroidal Neovascularization Drug Revenue Share by Players/Suppliers
Table United States Market Choroidal Neovascularization Drug Average Price (USD/Pcs) of Key Players/Suppliers (2012-2017)
Figure United States Market Choroidal Neovascularization Drug Average Price (USD/Pcs) of Key Players/Suppliers in 2016
Figure United States Choroidal Neovascularization Drug Market Share of Top 3 Players/Suppliers
Figure United States Choroidal Neovascularization Drug Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Choroidal Neovascularization Drug Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Choroidal Neovascularization Drug Product Category
Table United States Choroidal Neovascularization Drug Sales (K Pcs) by Region (2012-2017)
Table United States Choroidal Neovascularization Drug Sales Share by Region (2012-2017)
Figure United States Choroidal Neovascularization Drug Sales Share by Region (2012-2017)
Figure United States Choroidal Neovascularization Drug Sales Market Share by Region in 2016
Table United States Choroidal Neovascularization Drug Revenue (Million USD) and Market Share by Region (2012-2017)
Table United States Choroidal Neovascularization Drug Revenue Share by Region (2012-2017)
Figure United States Choroidal Neovascularization Drug Revenue Market Share by Region (2012-2017)
Figure United States Choroidal Neovascularization Drug Revenue Market Share by Region in 2016
Table United States Choroidal Neovascularization Drug Price (USD/Pcs) by Region (2012-2017)
Table United States Choroidal Neovascularization Drug Sales (K Pcs) by Type (2012-2017)
Table United States Choroidal Neovascularization Drug Sales Share by Type (2012-2017)
Figure United States Choroidal Neovascularization Drug Sales Share by Type (2012-2017)
Figure United States Choroidal Neovascularization Drug Sales Market Share by Type in 2016
Table United States Choroidal Neovascularization Drug Revenue (Million USD) and Market Share by Type (2012-2017)
Table United States Choroidal Neovascularization Drug Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Choroidal Neovascularization Drug by Type (2012-2017)
Figure Revenue Market Share of Choroidal Neovascularization Drug by Type in 2016
Table United States Choroidal Neovascularization Drug Price (USD/Pcs) by Types (2012-2017)
Figure United States Choroidal Neovascularization Drug Sales Growth Rate by Type (2012-2017)
Table United States Choroidal Neovascularization Drug Sales (K Pcs) by Application (2012-2017)
Table United States Choroidal Neovascularization Drug Sales Market Share by Application (2012-2017)
Figure United States Choroidal Neovascularization Drug Sales Market Share by Application (2012-2017)
Figure United States Choroidal Neovascularization Drug Sales Market Share by Application in 2016
Table United States Choroidal Neovascularization Drug Sales Growth Rate by Application (2012-2017)
Figure United States Choroidal Neovascularization Drug Sales Growth Rate by Application (2012-2017)
Table Cellphire, Inc. Basic Information List
Table Cellphire, Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Cellphire, Inc. Choroidal Neovascularization Drug Sales Growth Rate (2012-2017)
Figure Cellphire, Inc. Choroidal Neovascularization Drug Sales Market Share in United States (2012-2017)
Figure Cellphire, Inc. Choroidal Neovascularization Drug Revenue Market Share in United States (2012-2017)
Table Chrysalis BioTherapeutics, Inc. Basic Information List
Table Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Sales Growth Rate (2012-2017)
Figure Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Sales Market Share in United States (2012-2017)
Figure Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Revenue Market Share in United States (2012-2017)
Table Cleveland BioLabs, Inc. Basic Information List
Table Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Sales Growth Rate (2012-2017)
Figure Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Sales Market Share in United States (2012-2017)
Figure Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Revenue Market Share in United States (2012-2017)
Table Cumberland Pharmaceuticals, Inc. Basic Information List
Table Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Sales Growth Rate (2012-2017)
Figure Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Sales Market Share in United States (2012-2017)
Figure Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Revenue Market Share in United States (2012-2017)
Table Diffusion Pharmaceuticals Inc. Basic Information List
Table Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Sales Growth Rate (2012-2017)
Figure Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Sales Market Share in United States (2012-2017)
Figure Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Revenue Market Share in United States (2012-2017)
Table Eli Lilly and Company Basic Information List
Table Eli Lilly and Company Choroidal Neovascularization Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Eli Lilly and Company Choroidal Neovascularization Drug Sales Growth Rate (2012-2017)
Figure Eli Lilly and Company Choroidal Neovascularization Drug Sales Market Share in United States (2012-2017)
Figure Eli Lilly and Company Choroidal Neovascularization Drug Revenue Market Share in United States (2012-2017)
Table GNI Group Ltd. Basic Information List
Table GNI Group Ltd. Choroidal Neovascularization Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure GNI Group Ltd. Choroidal Neovascularization Drug Sales Growth Rate (2012-2017)
Figure GNI Group Ltd. Choroidal Neovascularization Drug Sales Market Share in United States (2012-2017)
Figure GNI Group Ltd. Choroidal Neovascularization Drug Revenue Market Share in United States (2012-2017)
Table Humanetics Corporation Basic Information List
Table Humanetics Corporation Choroidal Neovascularization Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Humanetics Corporation Choroidal Neovascularization Drug Sales Growth Rate (2012-2017)
Figure Humanetics Corporation Choroidal Neovascularization Drug Sales Market Share in United States (2012-2017)
Figure Humanetics Corporation Choroidal Neovascularization Drug Revenue Market Share in United States (2012-2017)
Table INSYS Therapeutics, Inc. Basic Information List
Table INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Sales Growth Rate (2012-2017)
Figure INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Sales Market Share in United States (2012-2017)
Figure INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Revenue Market Share in United States (2012-2017)
Table Meabco A/S Basic Information List
Table Meabco A/S Choroidal Neovascularization Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Meabco A/S Choroidal Neovascularization Drug Sales Growth Rate (2012-2017)
Figure Meabco A/S Choroidal Neovascularization Drug Sales Market Share in United States (2012-2017)
Figure Meabco A/S Choroidal Neovascularization Drug Revenue Market Share in United States (2012-2017)
Table Neumedicines Inc. Basic Information List
Table Onconova Therapeutics, Inc. Basic Information List
Table PharmaIN Corporation Basic Information List
Table Pluristem Therapeutics Inc. Basic Information List
Table ProCertus BioPharm Inc. Basic Information List
Table RDD Pharma Ltd. Basic Information List
Table RedHill Biopharma Ltd. Basic Information List
Table RxBio, Inc. Basic Information List
Table Soligenix, Inc. Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Choroidal Neovascularization Drug
Figure Manufacturing Process Analysis of Choroidal Neovascularization Drug
Figure Choroidal Neovascularization Drug Industrial Chain Analysis
Table Raw Materials Sources of Choroidal Neovascularization Drug Major Players/Suppliers in 2016
Table Major Buyers of Choroidal Neovascularization Drug
Table Distributors/Traders List
Figure United States Choroidal Neovascularization Drug Sales Volume (K Pcs) and Growth Rate Forecast (2017-2022)
Figure United States Choroidal Neovascularization Drug Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure United States Choroidal Neovascularization Drug Price (USD/Pcs) Trend Forecast (2017-2022)
Table United States Choroidal Neovascularization Drug Sales Volume (K Pcs) Forecast by Type (2017-2022)
Figure United States Choroidal Neovascularization Drug Sales Volume (K Pcs) Forecast by Type (2017-2022)
Figure United States Choroidal Neovascularization Drug Sales Volume (K Pcs) Forecast by Type in 2022
Table United States Choroidal Neovascularization Drug Sales Volume (K Pcs) Forecast by Application (2017-2022)
Figure United States Choroidal Neovascularization Drug Sales Volume (K Pcs) Forecast by Application (2017-2022)
Figure United States Choroidal Neovascularization Drug Sales Volume (K Pcs) Forecast by Application in 2022
Table United States Choroidal Neovascularization Drug Sales Volume (K Pcs) Forecast by Region (2017-2022)
Table United States Choroidal Neovascularization Drug Sales Volume Share Forecast by Region (2017-2022)
Figure United States Choroidal Neovascularization Drug Sales Volume Share Forecast by Region (2017-2022)
Figure United States Choroidal Neovascularization Drug Sales Volume Share Forecast by Region in 2022
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources